BRISBANE, Calif., May 04, 2017 -- CareDx, Inc. (NASDAQ:CDNA) announces that Palmetto GBA has released a draft local coverage determination (LCD) for AlloSure. AlloSure is the first and only non-invasive test that uses donor derived cell free DNA as a biomarker to directly measure allograft injury and identify the probability of active rejection.

 

"This marks an important milestone in making AlloSure available to kidney transplant patients," said Peter Maag, Chief Executive Officer at CareDx. "We are tracking against a commercial launch of AlloSure later in 2017 following the completion of reimbursement discussions. The draft LCD release underscores our leadership position in partnering with the transplant community on novel diagnostic solutions to improve patient management and long-term outcomes.”

Gross margin expands to 65 percent during first quarter

- Revenue guidance raised to $195-205 million for 2017, from $170-180 million;

- Guidance for completed Cologuard tests increased to at least 470,000 tests, from at least 415,000;

- 10,000 additional providers ordered Cologuard during the first quarter, and insurance coverage expanded to 78 percent.

 

MADISON, Wis., April 27, 2017 - Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $48.4 million and completed approximately 100,000 Cologuard tests during the quarter ended March 31, 2017. First-quarter 2017 revenues and completed Cologuard test volume grew 226 percent and 150 percent from the same period of 2016, respectively.

Akers Wellness iOS digital application approved by the Apple App Store

 

THOROFARE, NJ--(Marketwired - Apr 24, 2017) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L) ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that the Akers Wellness™ app, which enables users to track the results of Akers Wellness™ breath-based tests via their mobile device, has been approved by the Apple App Store and is now available for download on iOS devices. The Akers Wellness™ app has until now only been available for android devices on the Google Play Store. 

 

The app works in conjunction with BreathScan Lync™, the new bluetooth-enabled reading device from Akers Wellness™, and disposable breath-based test cartridges, to help promote, track and/or encourage choices related to general health and wellbeing.

PARSIPPANY, N.J., April 18, 2017 -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced that UnitedHealthcare, the largest health plan in the United States, has agreed to cover Interpace's ThyraMIR® test used in assessing indeterminate thyroid nodule fine needle aspirate (FNA) biopsies. The coverage is now in effect and is subject to members' specific benefit plan design. The UnitedHealthcare policy decision is consistent with the National Comprehensive Cancer Network (NCCN) Thyroid Carcinoma Guidelines, which recommend that clinicians consider the use of molecular testing to identify patients with indeterminate cytopathology results whose nodules are actually benign and can thus avoid surgery. Interpace is not currently a contracted, in-network lab provider with UnitedHealthcare. Interpace's ThyGenX® and ThyraMIR assays are now covered for approximately 250 million patients nationwide, including through Medicare, National, and Regional health plans. Medicare approved coverage for ThyraMIR in January 2016 (LCD L35396).